ACE2-ang-(1-7)-mas axis in brain: A potential target for prevention and treatment of ischemic stroke

Current Neuropharmacology

Volumn 11, Issue 2, 2013, Pages 209-217

  Jiang, Teng ^a   Gaoa, Li ^a   Lu, Jie ^b   Zhang, Ying Dong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin (1 7); Neuroprotection; Oxidative stress; Renin angiotensin system; Stroke

Indexed keywords

ACE2 ANGIOTENSIN (1-7) MAS AXIS; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; APOLIPOPROTEIN E; BRADYKININ; BRADYKININ B2 RECEPTOR; CYCLINE; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MEMBRANE METALLOENDOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL) PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROSTACYCLIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTICOAGULATION; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; HUMAN; HYPERTENSION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 84876743592     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X11311020007     Document Type: Article

References (96)

1. Kuklina, E.V.; Tong, X.; George, M.G.; Bansil, P. Epidemiology and prevention of stroke: a worldwide perspective. Expert. Rev. Neurother., 2012, 12(2), 199-208.
2. Jia, Q.; Liu, L.P.; Wang, Y.J. Stroke in China. Clin. Exp. Pharmacol. Physiol., 2010, 37(2), 259-264.
3. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; Fullerton, H.J.; Gillespie, C.; Hailpern, S.M.; Heit, J.A.; Howard, V.J.; Kissela, B.M.; Kittner, S.J.; Lackland, D.T.; Lichtman, J.H.; Lisabeth, L.D.; Makuc, D.M.; Marcus, G.M.; Marelli, A.; Matchar, D.B.; Moy, C.S.; Mozaffarian, D.; Mussolino, M.E.; Nichol, G.; Paynter, N.P.; Soliman, E.Z.; Sorlie, P.D.; Sotoodehnia, N.; Turan, T.N.; Virani, S.S.; Wong, N.D.; Woo, D.; Turner, M.B. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation, 2012, 125(1), e2-e220.
4. Feng, Y.; Xia, H.; Santos, R.A.; Speth, R.; Lazartigues, E. Angiotensinconverting enzyme 2: a new target for neurogenic hypertension. Exp. Physiol., 2010, 95(5), 601-606.
5. Zhang, C.; Zhao, Y.X.; Zhang, Y.H.; Zhu, L.; Deng, B.P.; Zhou, Z.L.; Li, S.Y.; Lu, X.T.; Song, L.L.; Lei, X.M.; Tang, W.B.; Wang, N.; Pan, C.M.; Song, H.D.; Liu, C.X.; Dong, B.; Zhang, Y.; Cao, Y. Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc. Natl. Acad. Sci. U.S.A., 2004, 107, 15886-15891.
6. Tesanovic, S.; Vinh, A.; Gaspari, T.A.; Casley, D.; Widdop, R.E. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 1606-1613.
7. Toton-Zuranska, J.; Gajda, M.; Pyka-Fosciak, G.; Kus, K.; Pawlowska, M.; Niepsuj, A.; Wolkow, P.; Olszanecki, R.; Jawien, J.; Korbut, R. AVE 0991-angiotensin-(1-7) receptor agonist, inhibits atherogenesis in ApoE-knockout mice. J. Physiol. Pharmacol., 2010, 61, 181-183.
8. Fraga-Silva, R.A.; Sorg, B.S.; Wankhede, M.; Dedeugd, C.; Jun, J.Y.; Baker, M.B.; Li, Y.; Castellano, R.K.; Katovich, M.J.; Raizada, M.K.; Ferreira, A.J. ACE2 activation promotes antithrombotic activity. Mol. Med., 2010, 16, 210-215.
9. Mecca, A.P.; Regenhardt, R.W.; O'Connor, T.E.; Joseph, J.P.; Raizada, M.K.; Katovich, M.J. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp. Physiol., 2011, 96, 1084-1096.
10. Jiang, T.; Gao, L.; Gun, J.; Lu, J.; Wang, Y.; Zhang, Y. Suppressing inflammation by inhibiting NF-κB pathway contributes to the neuroprotection of angiotensin-(1-7) in rats with permanent cerebral ischemia. Br. J. Pharmacol., 2012. doi: 10.1111/j.1476- 5381.2012.02105.x.
11. Schelling, P.; Hutchinson, J.S.; Ganten, U.; Sponer, G.; Ganten, D. Impermeability of the blood-cerebrospinal fluid barrier for angotensin-II in rats. Clin. Sci. Mol. Med. Suppl., 1976, 3, 399s-402s.
12. Rabelo, L.A.; Alenina, N.; Bader, M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens. Res., 2011, 34, 154-160.
13. Veerasingham, S.J.; Raizada, M.K. Brain rennin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br. J. Pharmacol., 2003, 139(2), 191-202.
14. Kamińska, M., Mogielnicki, A., Stankiewicz, A; Kramkowski, K.; Domaniewski, T.; Buczko, W.; Chabielska, E. Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats. J. Physiol. Pharmacol., 2005, 56(4), 571-585.
15. Senchenkova, E.Y.; Russell, J.; Kurmaeva, E.; Ostanin, D.; Granger, D.N. Role of T lymphocytes in angiotensin II-mediated microvascular thrombosis. Hypertension, 2011, 58(5), 959-965.
16. Daugherty, A.; Manning, M.W.; Cassis, L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest., 2000, 105(11), 1605-1612.
17. Chrissobolis, S.; Banfi, B.; Sobey, C.G.; Faraci, F.M. Role of Nox Isoforms in Angiotensin II-Induced Oxidative Stress and Endothelial Dysfunction in Brain. J. Appl. Physiol., 2012, 113(2), 184-191.
18. Fu, H.; Hosomi, N.; Pelisch, N. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. J. Hypertens., 2011, 29(11), 2210-2219
19. Horiuchi, M.; Mogi, M. Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage. Br. J. Pharmacol., 2011, 163(6), 1122-1130.
20. Tipnis, S.R.; Hooper, N.M.; Hyde, R.; Karran, E.; Christie, G.; Turner, A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem., 2000, 275(43), 33238-33243.
21. Doobay, M.F., Talman, L.S., Obr, T.D., Tian, X., Davisson, R.L., Lazartigues, E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292(1), R373-R381.
22. Gallagher, P.E.; Chappell, M.C.; Ferrario, C.M.; Tallant, E.A. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am. J. Physiol. Cell. Physiol., 2006, 290(2), C420-C426.
23. Hamming, I., Timens, W., Bulthuis, M.L.C.; Lely, A.T.; Navis, G.J.; van Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol., 2004, 203(2), 631-637.
24. Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.; Hsieh, F.; Acton, S.; Patane, M.; Nichols, A.; Tummino, P. Hydrolysis of biological peptides by human angiotensinconverting enzyme-related carboxypeptidase. J. Biol. Chem., 2002, 277(17), 14838-14843.
25. Becker, L.K.; Etelvino, G.M.; Walther, T.; Santos, R.A.S.; Campagnole- Santos, MJ. Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain. Am. J. Physiol. Heart. Circ. Physiol., 2007, 293(3), H1416-H1424.
26. Guo, F.; Liu, B.; Tang, F.; Lane, S.; Souslova, E.A.; Chudakov, D.M.; Paton, J.F.; Kasparov, S. Astroglia are a possible cellular substrate of angiotensin (1-7) effects in the rostral ventrolateral medulla. Cardiovasc. Res., 2010, 87(3), 578-584.
27. Kumar, M.; Grammas, P.; Giacomelli, F.; Wiener, J. Selective expression of c-mas proto-oncogene in rat cerebral endothelial cells. Neuroreport,1996, 8(1), 93-96.
28. Young, D.; O'Neill, K.; Jessell, T.; Wigler, M. Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain. Proc. Natl. Acad. Sci. U.S.A., 1988, 85(14), 5339-5342.
29. Santos, R.A.; Frezard, F.; Ferreira, A.J. Angiotensin-(1-7): blood, heart, and blood vessels. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 2005, 3(4), 383-391.
30. Santos, R.A.S.; Silva, A.C.S.; Maric, C.; Silva, D.M.; Machado, R.P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S.V.; Lopes, M.T.; Bader, M. Mendes, E.P.; Lemos, V.S. Campagnole-Santos, M.J. Schultheiss, H.P.; Speth, R.; Walther, T. Angiotensin-(1-7) is an endogenous ligand for the G proteincoupled receptor Mas. Proc. Natl. Acad. Sci. USA., 2003, 100(14), 8258-8263.
31. Chappell, M.C.; Brosnihan, K.B.; Diz, D.I.; Ferrario, C.M. Identification of angiotensin-(1-7) in rat brain. Evidence for differential processing of angiotensin peptides. J. Biol. Chem., 1989, 264(28), 16518-16523.
32. Trask, A.J.; Averill, D.B.; Ganten, D.; Chappell, M.C.; Ferrario, C.M. Primary role of angiotensin converting enzyme 2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am. J. Physiol. Heart. Circ. Physiol., 2007, 292(6), H3019-H3024.
33. Welches, W.R.; Brosnihan, K.B.; Ferrario, C.M. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci., 1993, 52, 1461-1480.
34. Chappell, M.C.; Pirro, N.T.; Sykes, A.; Ferrario, C.M. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension, 1998, 31(1 Pt 2), 362-367.
35. Allred, A.J.; Diz, D.I.; Ferrario, C.M.; Chappell, M.C. Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am. J. Physiol. Renal. Physiol., 2000, 279(5), F841-F850.
36. Yu, J.G.; Zhou, R.R.; Cai, G.J. From hypertension to stroke: mechanisms and potential prevention strategies. CNS Neurosci. Ther., 2011, 17(5), 577-584.
37. Schiffrin, E.L. Beyond blood pressure: the endothelium and atherosclerosis progression. Am. J. Hypertens., 2002, 15, 115S-122S.
38. Grassi, G.; Arenare, F.; Trevano, F.Q.; Dell'Oro, R.; Mancia, A.G. Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials. Curr. Hypertens. Rep., 2007, 9(4), 299-304.
39. Diz, D.I.; Garcia-Espinosa, M.A.; Gegick, S.; Tommasi, E.N.; Ferrario, C.M.; Ann Tallant, E.; Chappell, M.C.; Gallagher, P.E. Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp. Physiol., 2008, 93(5), 694-700.
40. Yamazato, M.; Yamazato, Y.; Sun, C.; Diez-Freire, C.; Raizada, M.K. Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension, 2007, 49(4), 926-931.
41. Xia, H.; Feng, Y.; Obr, T.D.; Hickman, P.J.; Lazartigues, E. Angiotensin II type 1 receptor-mediated reduction of angiotensinconverting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension, 2009, 53(2), 210-216.
42. Feng Y, Xia H, Cai Y, Halabi, C.M., Becker, L.K., Santos, R.A., Speth, R.C., Sigmund, C.D., Lazartigues, E. Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ. Res., 2010,106(2), 373-382.
43. Sriramula, S.; Cardinale, J.P.; Lazartigues, E.; Francis, J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc. Res., 2011, 92(3), 401-408.
44. Chaves, G.Z.; Caligiorne, S.M.; Santos, R.A.; Khosla, M.C.; Campagnole-Santos, M.J. Modulation of the baroreflex control of heart rate by angiotensin-(1-7) at the nucleus tractus solitarii of normotensive and spontaneously hypertensive rats. J. Hypertens., 2000, 18(12), 1841-1848.
45. Höcht, C.; Gironacci, M.M.; Mayer, M.A.; Schuman, M.; Bertera, F.M.; Taira, C.A. Involvement of angiotensin-(1-7) in the hypothalamic hypotensive effect of captopril in sinoaortic denervated rats. Regul. Pept., 2008, 146(1-3), 58-66.
46. Cerrato, B.D.; Frasch, A.P.; Nakagawa, P.; Longo-Carbajosa, N.; Peña, C.; Höcht, C.; Gironacci, M.M. Angiotensin-(1-7) upregulates central nitric oxide synthase in spontaneously hypertensive rats. Brain Res., 2012, 1453, 1-7.
47. Dobruch, J.; Paczwa, P.; Łoń, S.; Khosla, M.C.; Szczepańska-Sadowska, E. Hypotensive function of the brain angiotensin-(1-7) in Sprague Dawley and renin transgenic rats. J. Physiol. Pharmacol., 2003, 54, 371-381.
48. Guimaraes, P.S.; Santiago, N.M.; Xavier, C.H.; Fontes, M.A.; Santos, R.A.; Campagnole-Santos, M.J. Chronic infusion of angiotensin-(1-7) into the lateral ventricle of the brain attenuates hypertension in DOCA-salt rats. Am. J. Physiol. Heart. Circ. Physiol., 2012, 303(3), H393-H400
49. Xiao, L.; Gao, L.; Zucker, I.H. Angiotensin-converting enzyme 2 attenuates the angiotensin II-induced upregulation of angiotensin II type 1 receptor in CATH a neurons. Hypertension, 2009, 54, e70.
50. Feng, Y.; Yue, X.; Xia, H.; Bindom, S.M.; Hickman, P.J.; Filipeanu, C.M.; Wu, G.; Lazartigues, E. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ. Res., 2008, 102, 729-736.
51. Cai, G.J.; Miao, C.Y.; Xie, H.H.; Lu, L.H.; Su, D.F. Arterial baroreflex dysfunction promotes atherosclerosis in rats. Atherosclerosis, 2005, 183, 41-47.
52. Xiao, L.; Gao, L.; Lazartigues, E.; Zucker, I.H. Brain-selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances baroreflex function in chronic heart failure. Hypertension, 2011, 58, 1057-1065.
53. Campagnole-Santos, M.J.; Heringer, S.B.; Batista, E.N.; Khosla, M.C.; Santos, R.A. Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am. J. Physiol., 1992, 263, R89-R94.
54. Bomtempo, C.A.; Santos, G.F.; Santos, R.A.; Campagnole-Santos, M.J. Interaction of bradykinin and angiotensin-(1-7) in the central modulation of the baroreflex control of the heart rate. J. Hypertens., 1998, 16, 1797-1804.
55. Kar, S.; Gao, L.; Belatti, D.A.; Curry, P.L.; Zucker, I.H. Central angiotensin (1-7) enhances baroreflex gain in conscious rabbits with heart failure. Hypertension, 2011, 58, 627-634.
56. Zimmerman, M.C. Angiotensin II and angiotensin-1-7 redox signaling in the central nervous system. Curr. Opin. Pharmacol., 2011, 11, 138-143.
57. Calka, J.; Block, C.H. Angiotensin-(1-7) and nitric oxide synthase in the hypothalamo-neurohypophysial system. Brain. Res. Bull., 1993, 30, 677-685.
58. Sampaio, W.O.; Souza dos Santos, R.A.; Faria-Silva, R.; da Mata Machado, L.T.; Schiffrin, E.L.; Touyz, R.M. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt dependent pathways. Hypertension, 2007, 49, 185-192.
59. Nagae, A.; Fujita, M.; Kawarazaki, H.; Matsui, H.; Ando, K.; Fujita, T. Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in obesity-induced hypertension. Circulation, 2009, 119, 978-986.
60. Shi, P.; Diez-Freire, C.; Jun, J.Y.; Qi, Y.; Katovich, M.J.; Li, Q.; Sriramula, S.; Francis, J.; Sumners, C.; Raizada, M.K. Brain microglial cytokines in neurogenic hypertension. Hypertension, 2010, 56, 297-303.
61. Xia, H.; Suda, S.; Bindom, S.; Feng, Y.; Gurley, S.B.; Seth, D.; Navar, L.G.; Lazartigues, E. ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One, 2011, 6, e22682.
62. Xing, J.; Kong, J.; Lu, J.; Li, J. Angiotensin-(1-7) inhibits neuronal activity of dorsolateral periaqueductal gray via a nitric oxide pathway. Neurosci. Lett., 2012, 522, 156-161.
63. Gironacci, M.M.; Valera, M.S.; Yujnovsky, I.; Pena, C. Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats. Hypertension, 2004, 44, 783-787.
64. Lopez Verrilli, M.A.; Pirola, C.J.; Pascual, M.M.; Dominici, F.P.; Turyn, D.; Gironacci, M.M. Angiotensin-(1-7) through AT receptors mediates tyrosine hydroxylase degradation via the ubiquitin-proteasome pathway. J. Neurochem., 2009, 109, 326-335.
65. Yang, R.F., Yin, J.X.; Li, Y.L.; Zimmerman, M.C.; Schultz, H.D. Angiotensin-(1-7) increases neuronal potassium current via a nitric oxide-dependent mechanism. Am. J. Physiol. Cell. Physiol., 2011, 300, C58-64.
66. Arenillas, J.F. Intracranial atherosclerosis: current concepts. Stroke, 2011, 42, S20-23.
67. Bui, Q.T.; Prempeh, M.; Wilensky, R.L. Atherosclerotic plaque development. Int. J. Biochem. Cell. Biol., 2009, 41, 2109-2113.
68. Lovren, F.; Pan, Y.; Quan, A.; Teoh, H.; Wang, G.; Shukla, P.C.; Levitt, K.S.; Oudit, G.Y.; Al-Omran, M.; Stewart, D.J.; Slutsky, A.S.; Peterson, M.D.; Backx, P.H.; Penninger, J.M.; Verma, S. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart. Circ. Physiol., 2004, 295, H1377-1384.
69. Dong, B.; Zhang, C.; Feng, J.B.; Zhao, Y.X.; Li, S.Y.; Yang, Y.P.; Dong, Q.L.; Deng, B.P.; Zhu, L.; Yu, Q.T.; Liu, C.X.; Liu, B.; Pan, C.M.; Song, H.D.; Zhang, M.X.; Zhang, Y. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1270-1276.
70. Zhang, F.; Hu, Y.; Xu, Q.; Ye, S. Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. PLoS One 2010, 5, e12323.
71. Jawien, J.; Toton-Zuranska, J.; Gajda, M.; Niepsuj, A.; Gebska, A.; Kus, K.; Suski, M.; Pyka-Fosciak, G.; Nowak, B.; Guzik, T.J.; Marcinkiewicz, J.; Olszanecki, R.; Korbut, R. Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J. Physiol. Pharmacol., 2012, 63, 77-85.
72. Sheng-Long, C.; Yan-Xin, W.; Yi-Yi, H.; Ming, F.; Jian-Gui, H.; Yi-Li, C.; Wen-Jing, X.; Hong, M. AVE0991, a Nonpeptide Compound, Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation via Induction of Heme Oxygenase-1 and Downregulation of p-38 MAPK Phosphorylation. Int. J. Hypertens., 2012, 2012, 958298.
73. Fraga-Silva, R.A.; Pinheiro, S.V.; Gonçalves, A.C.; Alenina, N.; Bader, M.; Santos, R.A. The antithrombotic effect of angiotensin- (1-7) involves mas-mediated NO release from platelets. Mol. Med., 2008, 14, 28-35.
74. Kucharewicz, I.; Pawlak, R.; Matys, T.; Pawlak, D.; Buczko, W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension, 2002, 40, 774-779.
75. Allen, C.L.; Bayraktutan, U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int. J. Stroke, 2009, 4, 461-470.
76. Janero, D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic. Biol. Med., 1990, 9, 515-540.
77. Chen, H.; Yoshioka, H.; Kim, G.S.; Jung, J.E.; Okami, N.; Sakata, H.; Maier, C.M.; Narasimhan, P.; Goeders, C.E.; Chan, P.H. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid. Redox. Signal., 2011, 14, 1505-1517.
78. van der Spuy, W.J.; Pretorius, E. Interrelation between inflammation, thrombosis, and neuroprotection in cerebral ischemia. Rev. Neurosci., 2012, 23, 269-278.
79. Ridder, D.A.; Schwaninger, M. NF-kappaB signaling in cerebral ischemia. Neuroscience, 2009, 158, 995-1006.
80. Zhu, J.; Jiang, Y.; Wu, L.; Lu, T.; Xu, G.; Liu, X. Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia. Neuroscience, 2012, 202, 342-351
81. Chan, S.J.; Wong, W.S.; Wong, P.T.; Bian, J.S. Neuroprotective effects of andrographolide in a rat model of permanent cerebral ischaemia. Br. J. Pharmacol., 2010, 161, 668-679
82. Shwari, A.; Badgujar, L.; Phukan, B.; Bodhankar, S.L.; Thakurdesai, P. Protective effect of Etoricoxib against middle cerebral artery occlusion induced transient focal cerebral ischemia in rats. Eur. J. Pharmacol., 2011, 667, 230-237.
83. Veltkamp, R.; Rajapakse, N.; Robins, G.; Puskar, M.; Shimizu, K.; Busija, D. Transient focal ischemia increases endothelial nitric oxide synthase in cerebral blood vessels. Stroke, 2002, 33, 2704-2710.
84. Osuka, K.; Watanabe, Y.; Usuda, N.; Nakazawa, A.; Tokuda, M.; Yoshida, J. Modification of endothelial NO synthase through protein phosphorylation after forebrain cerebral ischemia/ reperfusion. Stroke, 2004, 35, 2582-2586.
85. Iadecola, C.; Zhang, F.; Casey, R.; Nagayama, M.; Ross, M.E. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J. Neurosci., 1997, 17, 9157-9164.
86. Moro, M.A.; Cardenas, A.; Hurtado, O.; Leza, J.C.; Lizasoain, I. Role of nitric oxide after brain ischaemia. Cell Calcium, 2004, 36, 265-275.
87. Zhang, Y.; Lu, J.; Shi, J.; Lin, X.; Dong, J.; Zhang, S.; Liu, Y,; Tong, Q. Central administration of angiotensin-(1-7) stimulates nitric oxide release and upregulates the endothelial nitric oxide synthase expression following focal cerebral ischemia/reperfusion in rats. Neuropeptides, 2008, 42, 593-600.
88. Chao, J.; Chao, L. Experimental therapywith tissue kallikrein against cerebral ischemia. Front. Biosci., 2006, 11, 1323-1327.
89. Noda, M.; Kariura, Y.; Pannasch, U.; Nishikawa, K.; Wang, L.; Seike, T.; Ifuku, M.; Kosai, Y.; Wang, B.; Nolte, C.; Aoki, S.; Kettenmann, H.; Wada, K. Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J. Neurochem., 2007, 101, 397-410.
90. Tom, B.; de Vries, R.; Saxena, P.R.; Danser, A.H.J. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension, 2001, 38, 95-99.
91. Lu, J.; Zhang, Y.; Shi, J. Effects of intracerebroventricular infusion of angiotensin-(1-7) on bradykinin formation and the kinin receptor expression after focal cerebral ischemia-reperfusion in rats. Brain Res., 2008, 1219, 127-135.
92. Santos, R.A.; Campagnole-Santos, M.J., Andrade, S.P. Angiotensin- (1-7): an update. Regul. Pept., 2000, 91, 45-62.
93. Xia, H.; Lazartigues, E. Angiotensin-converting enzyme 2 in the brain: properties and future directions. J. Neurochem., 2008, 107, 1482-1494.
94. Marques, F.D.; Ferreira, A.J.; Sinisterra, R.D.; Jacoby, B.A.; Sousa, F.B.; Caliari, M.V.; Silva, G.A.; Melo, M.B.; Nadu, A.P.; Souza, L.E.; Irigoyen, M.C.; Almeida, A.P.; Santos, R.A. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension, 2011, 57, 477-483.
95. Marques, F.D.; Melo, M.B.; Souza, L.E.; Irigoyen, M.C.; Sinisterra, R.D.; de Sousa, F.B.; Savergnini, S.Q.; Braga, V.B.; Ferreira, A.J.; Santos, R.A. Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats. Int. J. Hypertens., 2012, 2012, 795452.
96. Santos, R.A.; Ferreira, A.J. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc. Drug Rev., 2006, 24, 239-246.